---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-104531"
form_type: "8-K"
ticker: "NUVL"
cik: "0001861560"
company_name: "Nuvalent, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:22:23.197993+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nuvalent Q2 2025 net loss $99.7M; rolling NDA for zidesamtinib initiated

## Summary
- Net loss $99.7M; R&D $80.9M, G&A $23.7M; cash $1.0B funding into 2028.
- Rolling NDA for zidesamtinib (ROS1+ NSCLC) initiated; target completion Q3 2025; FDA RTOR pilot.
- ALKAZAR Phase 3 of neladalkib (ALK+ NSCLC) dosed; topline TKI pre-treated data expected year-end 2025.
- Preliminary data for neladalkib in ALK+ solid tumors at ESMO 2025 (Oct 17-21).
- Jason Waters promoted to SVP Commercial; Christy Oliger appointed to board.

## SEC filing metadata
- accession: 0000950170-25-104531
- form_type: 8-K
- ticker: NUVL
- cik: 0001861560
- company_name: Nuvalent, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861560/000095017025104531/0000950170-25-104531-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861560/000095017025104531/nuvl-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-104531
- JSON: https://secwatch.observer/filing/0000950170-25-104531.json
- Plain text: https://secwatch.observer/filing/0000950170-25-104531.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.